The late Ted Harada, who was my 2016 Stem Cell Person of the Year, was a powerful patient advocate for stem cells and for ALS patients. Each year I give out a Stem Cell Person of the Year Award including a $2,000 prize that I provide myself to the winner, and Ted won that last year. Continue reading
Ring the bell for a stem cell milestone.
There’s been a whole lot of commotion about the NEJM article yesterday documenting the experiences of three women with macular degeneration who were blinded by non-FDA approved stem cell eye injections of fat stem cells at a business in Florida, but in the same issue of the journal there also was some encouraging stem cell news that came in the form of essentially a mirror image of the bad news paper. We can call it the “stem cell good news-bad news” issue of NEJM.
The good news was the publication of the first paper on clinical use of IPS cell-derivatives in a human patient. A big milestone. This groundbreaking manuscript comes from the pioneering team in Japan led by stem cell scholar Dr. Masayo Takahashi. I’ve written extensively in the past about the work of Takahashi and her team with IPS cells, and she received my Stem Cell Person of the Year Award back in 2014.
In the new paper they detail their data from the clinical study using sheets of retinal pigmented epithelial cells (RPEs) made from IPS cells in this case derived from the patient herself for autologous use. Remarkably in Figure 1C (above) you can see the actual transplanted RPE sheet in the eye of the patient (see dark area indicated by white arrow). The most encouraging part of this study was that the patient’s vision remained stable (rather than declining as expected) following the treatment. Was that due to the transplant? We can’t be sure.
Also, this is just a beginning as it is just one patient, but it is very exciting and represents a big milestone for the IPS cell and broader stem cell field, providing real hope for patients with vision loss along with parallel ESC-based clinical trial work as well.
This paper contrasts so much with the report from the other one in the same issue on the terrible outcomes from the stem cell clinic’s use of fat stem cells in the eye. While the use of fat stem cells themselves is highly questionable in my view for this application, the biggest differences between the two approaches is that the Takahashi team work was extremely rigorous, careful, based on extensive preclinical studies, had governmental approval, and was in essence science-based clinical medicine.
For instance, the Takahashi team was appropriately cautious with Patient 2 since the cells exhibited some genomic changes. At least in part for that reason, moving forward this clinical work will primarily focus on allogeneic use of IPS cells via an IPS cell bank being developed by Shinya Yamanaka.
We can also look to other future IPS cell-based trials coming on-line including for Parkinson’s Disease and other conditions, which are likely to be allogeneic as well in Japan, but probably autologous here in the U.S.
I love a good stem cell milestone!
The voting on the 20 nominees for Stem Cell Person of the Year finished at midnight last night.
After more than 1,000 votes, we have the top 10 finalists.
These ten are some of the most remarkable people in the world of stem cells today. They have all had great impact, but in very diverse ways.
They run the spectrum from patient advocates to the President of CIRM to a host of top stem cell researchers. Patient advocates Ted Harada and Judy Roberson have the top two spots in terms of votes.
Now I have the tough task of picking just one winner as the Stem Cell Person of the Year. The awardee wins international recognition as the top outside the box thinker and positive impactor of the year and a $2,000 prize. You can read more about all the 20 people who were nominated here.
Vote on your pick for the top stem cell outside the box thinker and positive impactor in 2016 from the 20 choices below. The top 10 vote getters will be finalists from which I will have the tough task of picking the one winner as Stem Cell Person of the Year along with the $2,000 prize and recognition.
You can vote once per day. The voting closes in 10 days on December 15th at 11:59pm Pacific Time. Read more about the 20 nominees here.
Nominations are open starting today for the Stem Cell Person of the Year Award for 2016. Please email me your nominations: knoepflerATucdavisDOTedu.
This is a unique award as it is given to an individual who has taken risks to help others within the stem cell field and they based their actions on outside-the-box thinking.
Another unusual aspect is that anyone is eligible for the prize whether you are a scientist, physician, patient, writer, student, etc. There are also no geographic restrictions.
The winner receives recognition as a positive leader in this arena and a $2,000 cash prize that I award myself out of pocket.
Nominations will close one month from today on October 15th.
The nominations I receive will then be subject to an Internet vote and the top 50% will be the finalists, from which I will choose the winner. While I alone choose the winner, I often get feedback from leaders around the globe in the stem cell and regenerative medicine field.
Previous winners include these stellar stem cell leaders:
- Top stem cell scientist Jeanne Loring in 2015. Note that Jeanne deferred getting her $2,000 prize money, which I then gave to Summit for Stem Cell, an amazing patient-based stem cell organization.
- Pioneering vision and pluripotent stem cell clinical researcher, Masayo Takahashi in 2014.
- Neural stem cell scientist and very effective Italian politician Elena Cattaneo in 2013.
- Stem cell patient advocate Roman Reed in 2012.
Who will win the Stem Cell Person of the Year Award for 2016? Send me your nominations.